PAVmed completes $45M financing, eliminates convertible debt; Q4 net loss $1.8M

PAVmed Inc.

PAVmed completed $30M Series D preferred offering and $15M senior secured note, eliminating all outstanding convertible securities.
GAAP net loss attributable to common stockholders $1.8M ($2.05 per share diluted); non-GAAP adjusted loss $0.9M ($1.05 per share).
Lucid Diagnostics recognized $1.5M EsoGuard revenue in Q4 2025, processed 3,664 tests; awarded VA contract for ~9M veterans.
Veris Health completed EHR integration with OSU James Cancer Hospital; targeting late 2026 FDA submission for implantable monitor.
PAVmed appointed Joseph Virgilio as CBO of Medical Devices and licensed endoscopic esophageal imaging technology from Duke University.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

PAVmed Inc. reported financial results for year ended December 31, 2025.

Period: year ended December 31, 2025
Result: reported results

Exact text from the filing

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PAVmed Inc. reported three months ended December 31, 2025 results: net income approximately $1.8 million, EPS $(2.05) per common share on a diluted basis.

Period: three months ended December 31, 2025
Net income: approximately $1.8 million
EPS: $(2.05) per common share on a diluted basis
Result: reported results

Exact text from the filing

For the three months ended December 31, 2025, Operating expenses were approximately $6.9 million which include stock-based compensation expenses of $0.3 million. GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per common share on a diluted basis.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013477

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.